Thrombocytopenia with Tedizolid and Linezolid

Antimicrob Agents Chemother. 2017 Dec 21;62(1):e01453-17. doi: 10.1128/AAC.01453-17. Print 2018 Jan.

Abstract

Several studies have suggested the risk of thrombocytopenia with tedizolid, a second-in-class oxazolidinone antibiotic (approved June 2014), is less than that observed with linezolid (first-in-class oxazolidinone). Using data from the Food and Drug Administration adverse event reporting system (July 2014 through December 2016), we observed significantly increased risks of thrombocytopenia of similar magnitudes with both antibiotics: linezolid reporting odds ratio [ROR], 37.9 (95% confidence interval [CI], 20.78 to 69.17); tedizolid ROR, 34.0 (95% CI, 4.67 to 247.30).

Keywords: drug safety; linezolid; pharmacovigilance; tedizolid; thrombocytopenia.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / adverse effects*
  • Humans
  • Linezolid / adverse effects*
  • Oxazolidinones / adverse effects*
  • Tetrazoles / adverse effects*
  • Thrombocytopenia / chemically induced*

Substances

  • Anti-Bacterial Agents
  • Oxazolidinones
  • Tetrazoles
  • tedizolid
  • Linezolid